The global disseminated intravascular coagulation (DIC) treatment market is expected to garner a market value of USD 500 million in 2023 and is expected to accumulate a market value of USD 814.45 million by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for disseminated intravascular coagulation (DIC) treatment registered a CAGR of 4% in the historical period 2018 to 2022.
The Disseminated Intravascular Coagulation (DIC) Treatment market is a segment of the healthcare industry that deals with the effective management of Disseminated Intravascular Coagulation (DIC). The Disseminated Intravascular Coagulation (DIC) Treatment market offers a range of products and services for the management and treatment of DIC. The market for DIC treatments is largely driven by the increasing incidence of underlying conditions such as cancer, sepsis, and obstetric complications, as well as advancements in diagnostic and treatment technologies.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 500 Million |
| Anticipated Forecast Value (2033) | USD 814.45 Million |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider Future Market Insights- the market for Disseminated Intravascular Coagulation (DIC) Treatment reflected a value of 4% during the historical period, 2018 to 2022.
The increasing incidence of underlying conditions such as cancer, sepsis, and obstetric complications that can lead to DIC is driving the demand for DIC treatments. Studies suggest that estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). Treatment for Disseminated Intravascular Coagulation (DIC) involves addressing the underlying condition that is causing the disorder, as well as treating the symptoms of DIC itself.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for Disseminated Intravascular Coagulation (DIC) Treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Disseminated Intravascular Coagulation (DIC) Treatments is fuelling the market growth. Thus, the market for Disseminated Intravascular Coagulation (DIC) Treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Increased Prevalence of Disseminated Intravascular Coagulation (DIC) in Elderly Population to Push the Market Growth
The global market for disseminated intravascular coagulation (DIC) treatment is driven by the growing advancements in treatment technologies, the development of new diagnostic technologies, and the availability of more effective treatments. In addition, increased awareness of DIC, especially amongst the geriatric population which is at higher risk of developing underlying conditions that can lead to DIC, has led to a higher healthcare expenditure globally contributing to the growth of the market. Furthermore, the prevalence of Disseminated Intravascular Coagulation (DIC) is high in low and middle-income countries, offering a significant market opportunity for companies to expand their product offerings and cater to the growing demand for minimally invasive treatments for DIC, by developing new, less invasive treatments.
In 2021, a new tool created by researchers to tackle disseminated intravascular coagulation (DIC) was announced. Although the technology was yet to undergo clinical trials, studies in rat models and on blood from DIC patients have shown promise. Brown and her team created a method using nanogel spheres. These spheres are specifically designed to attach to fibrin, the primary protein present in blood clots. By doing so, the spheres travel through the bloodstream and once they encounter a blood clot, they adhere to the fibrin. The goal is to find a clinical solution to this dilemma and the new tool, using nanogel spheres, offers promising results. The spheres are designed to bind to the main protein in clots, fibrin, and are loaded with tissue-type plasminogen activator, a drug that dissolves clots.
Expensive Cost of Treatment to restrict Market Growth
The market is projected to get significantly affected by challenging factors such as limited availability and high cost of advanced Disseminated Intravascular Coagulation (DIC) Treatment options.
Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, are expected to hinder the market growth. Furthermore, various alternative treatments for underlying conditions, such as chemotherapy for cancer or antibiotics for sepsis, can limit demand for DIC treatments.
Improvement in healthcare spending propelling growth of Disseminated Intravascular Coagulation (DIC) Treatment in Asia Pacific
The Asia Pacific is expected to exhibit the significant growth rate of all regions over the forecast period, with a CAGR of 2.5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Disseminated Intravascular Coagulation (DIC) Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point of care approach to healthcare. Increasing number of hospitals in India and China makes a promising market for the market worldwide.
Technological Advancements Shaping Landscape for Disseminated Intravascular Coagulation (DIC) Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.
The Centre for Disease Control and Prevention (CDC), in its December 2022 update reported that, in 2021, the incidence of coronary heart disease and heart attack among adults over 18 years old in the United States was 4.9% and 3% respectively. The high prevalence of heart diseases in developed nations will drive the growth of the market. Additionally, the increasing number of research partnerships and favorable regulatory policies also play a significant role in driving the growth of the market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
D-Dimer segment is expected to hold a major market share
The growing incidence of Venous Thromboembolism (VTE) and the increasing occurrence of pulmonary and cardiovascular diseases caused by blood clots are also contributing to the demand for D-dimer testing. The use of automated analyzers for D-dimer testing has increased in recent years and is expected to grow further in the future. Research has shown that these analyzers significantly reduce laboratory processing time and improve clinical decision making. Furthermore, ongoing R&D efforts to expand the use of analyzers also drives their usage.
Considering these figures, the D-Dimer diagnosis segment of Disseminated Intravascular Coagulation (DIC) is projected to push the market growth. Such a high prevalence of the disease is anticipated to bolster the demand for Disseminated Intravascular Coagulation (DIC) Treatment among the patient population over the coming years.
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the DIC treatment facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target disease.
Key players in the market include pharmaceutical companies such as Pfizer, Inc., Pfizer Inc., Roche Holding AG, Sanofi, Bayer AG and Johnson & Johnson, as well as healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 500 million |
| Market Value in 2033 | USD 814.45 million |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Diagnosis, End-User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Middle East & Africa; Oceania |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd.; Mylan N.V; Teva Pharmaceutical Industries Ltd.; Sanofi S.A; Pfizer Inc.; GSK Plc.; Novartis AG; Bayer AG; Eli Lily and Company; Merck & Co. Inc.; Allergan Plc.; AbbVie Inc.; Merck KGaA; Hikma Pharmaceuticals PLC |
| Customization | Available Upon Request |
China, India, and Japan are key Asian countries in the market.
Hospital sector is gaining significant traction in the market.
A CAGR of 7% is expected for the DIC treatment market by 2033.
The DIC therapy market is currently valued at USD 500 million.
The DIC therapy market is anticipated to reach USD 814.45 million by 2033.
| Market Value (2023) | USD 3,038.9 million |
|---|---|
| Expected Forecast Value (2033) | USD 5,680.7 million |
| Projected CAGR (2023 to 2033) | 6.5% |
| Estimated Market Value (2022) | USD 1.1 Billion |
|---|---|
| Projected Market Value (2032) | USD 2.1 Billion |
| Value-based CAGR (2022 to 2032) | 6.8% |
Explore Therapy Area Insights
View Reports
Disseminated Intravascular Coagulation (DIC) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
